Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

Maris Mezeckis; Vesprini Danny; Buryk Vladyslav; Miszczyk Leszek; Vjaters Egils

Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

Maris Mezeckis, Vesprini Danny, Buryk Vladyslav, Miszczyk Leszek, Vjaters Egils

Research output: Contribution to journal › Article › peer-review

Abstract

Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

Original language	English
Pages (from-to)	95-103
Number of pages	9
Journal	Journal of Radiosurgery and SBRT
Volume	8
Issue number	2
Publication status	Published - Dec 2022
Externally published	Yes

Field of Science*

3.2 Clinical medicine

Publication Type*

1.3. Anonymously reviewed scientific article published in a journal with an international editorial board and is available in another indexed database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{6dbbd540b4d841e28453fb4e9ddff287,

title = "Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer",

abstract = "Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.",

author = "Maris Mezeckis and Vesprini Danny and Buryk Vladyslav and Miszczyk Leszek and Vjaters Egils",

note = "{\textcopyright} 2022 Old City Publishing, Inc.",

year = "2022",

month = dec,

language = "English",

volume = "8",

pages = "95--103",

journal = "Journal of Radiosurgery and SBRT",

issn = "2156-4639",

publisher = "Old City Publishing",

number = "2",

}

TY - JOUR

T1 - Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

AU - Mezeckis, Maris

AU - Danny, Vesprini

AU - Vladyslav, Buryk

AU - Leszek, Miszczyk

AU - Egils, Vjaters

PY - 2022/12

Y1 - 2022/12

N2 - Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

AB - Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year's multiple variations in treatment, techniques have been reported making comparisons more complicated. This review's objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.

UR - https://www.ncbi.nlm.nih.gov/pmc/issues/417512/

UR - https://pubmed.ncbi.nlm.nih.gov/36275129/

M3 - Article

C2 - 36275129

SN - 2156-4639

VL - 8

SP - 95

EP - 103

JO - Journal of Radiosurgery and SBRT

JF - Journal of Radiosurgery and SBRT

IS - 2

ER -

Overview of the current role of stereotactic body radiotherapy in the treatment of unfavorable intermediate- and high-risk prostate cancer

Abstract

Field of Science*

Publication Type*

UN SDGs

Other files and links

Fingerprint

Cite this